GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » LungLife AI Inc (LSE:LLAI) » Definitions » Current Deferred Revenue

LungLife AI (LSE:LLAI) Current Deferred Revenue : £0.00 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is LungLife AI Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

LungLife AI's current deferred revenue for the quarter that ended in Dec. 2023 was £0.00 Mil.

LungLife AI Current Deferred Revenue Historical Data

The historical data trend for LungLife AI's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LungLife AI Current Deferred Revenue Chart

LungLife AI Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Deferred Revenue
Get a 7-Day Free Trial - - - - -

LungLife AI Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

LungLife AI Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of LungLife AI's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


LungLife AI (LSE:LLAI) Business Description

Traded in Other Exchanges
N/A
Address
2545 W. Hillcrest Drive, Suite 140, Thousand Oaks, CA, USA, 91320
LungLife AI Inc is a diagnostic company focused on the early detection of lung cancer from a simple blood draw enhanced by artificial intelligence. Its LungLB Test is a blood-based tool developed to provide clinicians the information needed to make informed decisions about the management of lung nodules and lung cancer.

LungLife AI (LSE:LLAI) Headlines

No Headlines